Somatic Systems, Inc. (SMAS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Somatic Systems, Inc. (SMAS) trades at $0.00. Somatic Systems, Inc. offers a drug-free, non-surgical approach to treating movement disorders, musculoskeletal problems, and pain relief. Market cap: $1.46M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SMAS: SMAS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SMAS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SMAS: 1/1 perspectives are bearish.
How is this calculated? →Somatic Systems, Inc. (SMAS) Healthcare & Pipeline Overview
Somatic Systems, Inc. provides non-invasive, drug-free treatments for movement disorders and musculoskeletal pain, differentiating itself through hands-on therapy and exercise programs. Operating within the medical care facilities sector, the company addresses a growing demand for alternative pain management solutions.
What Is the Investment Thesis for SMAS?
Somatic Systems, Inc. presents a unique value proposition within the healthcare sector, offering a drug-free, non-surgical approach to pain management. The company's high gross margin of 90.9% indicates strong pricing power and efficient service delivery. Growth catalysts include expanding its geographic footprint and increasing adoption of alternative pain management therapies. However, the company's negative profit margin of -222.6% raises concerns about its financial sustainability. The company's beta of -127.87 suggests an inverse correlation with the market, potentially offering diversification benefits. Investors should carefully consider the company's profitability challenges and competitive landscape before investing.
Based on FMP financials and quantitative analysis
SMAS Key Highlights
- Somatic Systems, Inc. operates in the healthcare sector, providing drug-free and non-surgical pain management solutions.
- The company boasts a high gross margin of 90.9%, indicating efficient service delivery and strong pricing power.
- Somatic Systems, Inc. has a negative profit margin of -222.6%, signaling potential financial sustainability concerns.
- The company's beta of -127.87 suggests an inverse correlation with the market, potentially offering diversification benefits.
- Somatic Systems, Inc. was founded in 1987 and has offices in Massachusetts, Virginia, and New York.
Who Are SMAS's Competitors?
SMAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDGEF Medigene AG | $2.59 | +0.00% | $38.17M | 48 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMAS's Key Strengths?
- Drug-free and non-surgical approach.
- Experienced therapists and proven techniques.
- High gross margin.
- Addresses a growing demand for alternative pain management.
What Are SMAS's Weaknesses?
- Negative profit margin.
- Limited geographic presence.
- Dependence on hands-on therapy, limiting scalability.
- Unknown Disclosure Status
What Could Drive SMAS Stock Higher?
- Potential partnerships with insurance providers to increase patient access.
- Expansion into telehealth services to reach a wider audience.
- Increasing demand for alternative pain management therapies.
- Development of specialized programs for specific conditions.
What Are the Key Risks for SMAS?
- Negative profit margin raises concerns about financial sustainability.
- Competition from traditional medical practices and physical therapy clinics.
- Changes in healthcare regulations and reimbursement policies.
- Limited geographic presence restricts market reach.
- Dependence on hands-on therapy limits scalability.
What Are the Growth Opportunities for SMAS?
- Expansion into Telehealth Services: Somatic Systems, Inc. can leverage telehealth to expand its reach beyond its physical locations. The telehealth market is projected to reach $555.9 billion by 2033, growing at a CAGR of 22.5% from 2023 to 2033. By offering virtual consultations and exercise programs, Somatic Systems can tap into this growing market and serve a wider range of patients, particularly those in remote areas or with mobility limitations. This expansion could be implemented within the next 1-2 years.
- Partnerships with Insurance Providers: Securing partnerships with major health insurance providers can significantly increase patient access and reduce out-of-pocket costs. Negotiating coverage for Somatic Systems' therapies would make them more accessible to a broader population. This initiative could be pursued over the next 2-3 years, potentially leading to a substantial increase in patient volume and revenue.
- Development of Specialized Programs for Specific Conditions: Creating tailored programs for specific conditions, such as arthritis, fibromyalgia, or sports injuries, can attract a larger patient base. These specialized programs can be marketed directly to individuals suffering from these conditions, as well as to healthcare professionals who treat them. This strategy can be implemented within the next year, enhancing the company's reputation and market share.
- Franchise Expansion: Somatic Systems, Inc. could explore a franchise model to expand its geographic footprint more rapidly. Franchising would allow the company to leverage the capital and expertise of franchisees to open new locations in underserved markets. This expansion strategy could be implemented over the next 3-5 years, creating a network of Somatic Systems clinics across the country.
- Integration with Wellness Programs: Partnering with corporate wellness programs to offer Somatic Systems' therapies to employees can provide a steady stream of patients. Many companies are increasingly investing in employee wellness initiatives to improve productivity and reduce healthcare costs. Integrating Somatic Systems' services into these programs can create a win-win situation for both the company and its employees. This partnership strategy can be pursued within the next year, providing a consistent revenue stream.
What Opportunities Does SMAS Have?
- Expansion into telehealth services.
- Partnerships with insurance providers.
- Development of specialized programs for specific conditions.
- Franchise expansion.
What Threats Does SMAS Face?
- Competition from traditional medical practices and physical therapy clinics.
- Changes in healthcare regulations and reimbursement policies.
- Potential for new and more effective pain management therapies.
- Economic downturn affecting patient affordability.
What Are SMAS's Competitive Advantages?
- Proprietary system of natural movement techniques.
- Experienced therapists trained in the Somatic Systems method.
- Strong reputation for providing effective pain relief and improved mobility.
What Does SMAS Do?
Somatic Systems, Inc., founded in 1987 and headquartered in Northampton, Massachusetts, offers a unique approach to treating movement disorders, musculoskeletal problems, and pain relief. Originally named Pivotal Technology, Inc., the company rebranded to Somatic Systems, Inc. to better reflect its core mission. The company's system revolves around natural, non-invasive movement techniques delivered through one-hour hands-on sessions, therapeutic exercise classes, and prescribed home exercises. These methods aim to alleviate pain and limitations stemming from accidents, trauma, and repetitive stress, addressing conditions like back pain, knee pain, joint problems, carpal tunnel syndrome, TMJ, scoliosis, bursitis, sciatica, headaches, and tendonitis. Somatic Systems, Inc. also caters to athletes, offering performance enhancement and injury prevention programs. With additional offices in Virginia Beach, Virginia, and New York, New York, the company extends its reach to serve a broader clientele seeking alternative pain management solutions.
What Products and Services Does SMAS Offer?
- Provides drug-free and non-surgical treatments for movement disorders.
- Offers hands-on therapy sessions using natural movement techniques.
- Conducts therapeutic exercise classes to improve mobility and reduce pain.
- Prescribes home exercises to reinforce therapy and promote long-term recovery.
- Treats conditions such as back pain, knee pain, and carpal tunnel syndrome.
- Offers performance gains and injury prevention programs for athletes.
- Addresses pain and limitations resulting from accidents, trauma, and repetitive stress.
How Does SMAS Make Money?
- Generates revenue through one-hour hands-on therapy sessions.
- Offers therapeutic exercise classes for group sessions.
- Provides customized home exercise programs for individual patients.
What Industry Does SMAS Operate In?
Somatic Systems, Inc. operates within the medical care facilities industry, a segment of the broader healthcare sector. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic pain, and a growing demand for alternative and non-invasive treatments. The competitive landscape includes traditional medical practices, physical therapy clinics, and other alternative medicine providers. Somatic Systems differentiates itself through its specific focus on natural movement techniques and hands-on therapy.
Who Are SMAS's Key Customers?
- Individuals suffering from movement disorders and musculoskeletal problems.
- Patients seeking drug-free and non-surgical pain relief options.
- Athletes looking to improve performance and prevent injuries.
SMAS Financials
Bull Case vs Bear Case
Bull Case
- Drug-free and non-surgical approach.
- Experienced therapists and proven techniques.
- High gross margin.
- Addresses a growing demand for alternative pain management.
Bear Case
- Negative profit margin.
- Limited geographic presence.
- Dependence on hands-on therapy, limiting scalability.
- Unknown Disclosure Status
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SMAS Latest News
No recent news available for SMAS.
SMAS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMAS.
Price Targets
Wall Street price target analysis for SMAS.
SMAS MoonshotScore
What does this score mean?
The MoonshotScore rates SMAS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Steven Aronstein
CEO
Steven Aronstein serves as the CEO of Somatic Systems, Inc. His background includes extensive experience in healthcare management and a deep understanding of alternative pain management therapies. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise in strategic planning and business development has been instrumental in shaping the company's direction.
Track Record: Under Steven Aronstein's leadership, Somatic Systems, Inc. has expanded its service offerings and strengthened its market position. He has focused on building strategic partnerships and improving operational efficiency. Key achievements include increasing patient volume and enhancing the company's reputation for providing effective pain relief.
SMAS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX or OTCQB. These companies often have limited operating history, emerging technologies, or face financial challenges. Investing in OTC Other stocks carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to less stringent listing requirements and reduced regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to listed companies.
- Limited regulatory oversight and investor protection.
- Going concern risk due to financial instability.
- Verify the company's registration and legal standing.
- Review available financial statements and assess financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity and trading volume of the stock.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC investing.
- Company has been in business since 1987.
- Physical office locations in multiple states.
- Offers a specific and defined service.
- CEO is identified.
Common Questions About SMAS (Healthcare)
What does Somatic Systems, Inc. do?
Somatic Systems, Inc. provides drug-free and non-surgical approaches to treating movement disorders, musculoskeletal problems, and pain relief. The company offers a system that uses natural, non-invasive movement techniques conducted through one-hour hands-on sessions, therapeutic exercise classes, and home exercises. This system aims to relieve pain and limitations resulting from accidents, trauma, and repetitive stress, addressing conditions like back pain, knee pain, joint problems, and carpal tunnel syndrome. Somatic Systems also offers performance gains and injury prevention for athletes.
What do analysts say about SMAS stock?
As of 2026-03-17, there is no available analyst coverage for Somatic Systems, Inc. (SMAS). Given its OTC Other listing and limited financial disclosure, formal analyst ratings and price targets are unlikely. Investors should conduct their own thorough due diligence and assess the company's financial health, business model, and growth prospects independently. Key valuation metrics, such as price-to-sales or price-to-earnings, are not readily available due to the lack of comprehensive financial reporting.
What are the main risks for SMAS?
The main risks for Somatic Systems, Inc. include its negative profit margin, which raises concerns about its long-term financial sustainability. The company also faces competition from traditional medical practices and physical therapy clinics. Changes in healthcare regulations and reimbursement policies could negatively impact its revenue. Additionally, its limited geographic presence and dependence on hands-on therapy restrict its market reach and scalability. As an OTC stock, SMAS carries additional risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for SMAS?
Evaluate SMAS on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SMAS data refresh on this page?
SMAS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SMAS's recent stock price performance?
Somatic Systems, Inc. (SMAS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Drug-free and non-surgical approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SMAS overvalued or undervalued right now?
Valuing Somatic Systems, Inc. (SMAS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SMAS?
Before investing in Somatic Systems, Inc. (SMAS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited, impacting the depth of analysis.
- OTC status introduces higher risk and uncertainty.